Auckland, New Zealand—Orion Health (OHE:NZX/ASX) today announced the appointment of Ronald Andrews as an independent director of the company.

Mr Andrews has close to 30 years in governance and executive roles in the US Clinical and Molecular Diagnostics industry. He sits on the Board of Directors for several companies, both public and private, and is active on a number of charitable boards. He has extensive experience working with the US government in Washington and speaks regularly to industry groups.

Mr Andrews served as the President of the Genetic Science Division for Thermo Fisher Scientific until December 2014. Prior to this he held a number of high profile executive roles including President of the Medical Sciences Venture within the Life Technologies Corporation, and he served as Chief Executive Officer of Clarient, a public company on the NASDAQ, which was sold to General Electric Healthcare in December 2010.

Orion Health Chairman Andrew Ferrier says the appointment of Mr Andrews will strengthen the capability of the Board, also boosting its number from five to six members. Mr Andrews will serve as a member of the People Development, Nominations and Remuneration Committee.

“We are fortunate that Ronnie has agreed to serve on the Orion Health Board and we look forward to the contribution he will make to our company’s growth” Mr Ferrier says.

“Ronnie brings to the Board a wealth of experience in the US health technology sector and his insights will not only assist us in our largest market, North America, but will be extremely valuable as we expand into new territories globally.”

The Board has determined that Mr Andrews is an independent director in accordance with NZX Listing Rules 3.3.2 and 3.3.3(b).

Media Contacts:

Sarah Putt
Corporate Marketing Manager
M: +64 21 610 592